Table 2:

Summary of confirmed objective response per blinded independent central review in the intention-to-treat population

Variable*	Nivolumab plus cabozantinib (N=323)	Sunitinib (N=328)
Confirmed objective response, %	56	28
(95% CI)	(50–61)	(24–34)
Confirmed best overall response, n (%)
Complete response	40 (12)	17 (5)
Partial response	140 (43)	76 (23)
Stable disease	105 (33)	134 (41)
Progressive disease	20 (6)	45 (14)
Unable to determine	18 (6)	55 (17)
Not reported	0	1 (<1)
Median time to response (IQR), months	2·8 (2·8–4·2)	4·2 (2·8–7·1)
Median duration of response (95% CI), months	23·1 (20·2–27·9)	15·1 (9·9–20·5)

^*Response was assessed according to RECIST v1.1, per blinded independent central review.

IQR=interquartile range. RECIST=Response Evaluation Criteria in Solid Tumors.